

# Mazdutide tops semaglutide in head-to-head study for type 2 diabetes and obesity

Market Event Summary

# Mazdutide demonstrates superior efficacy profile over semaglutide

## The DREAMS-3 study design

- DREAMS-3 is an open-label H2H study comparing mazdutide (dual GCGR / GLP-1 RA) with semaglutide (GLP-1 RA) in Chinese participants with early T2D and obesity.
- The objective of the study is to compare the efficacy and safety of mazdutide versus semaglutide. The primary endpoint is the proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline at week 32.
- The study randomized 349 patients in China to receive once-weekly injections of semaglutide 0.25 mg or mazdutide 2 mg as starting doses.

## Clinical results

- On October 28, 2025, Innovent Biologics released top-line data from the DREAMS-3 study indicating that mazdutide met its primary endpoint.
- The results showed that mazdutide demonstrated superior efficacy to semaglutide. The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48% in the mazdutide group versus 21% in the semaglutide group.
- At week 32, mean reduction in HbA1c was 2.03% with mazdutide and 1.84% with semaglutide, while mean body weight reduction was 10.29% and 6.00%, respectively. Mazdutide's overall safety profile was consistent with previous studies and comparable to semaglutide, with gastrointestinal events being the most common adverse effects.

## Clarivate's takeaways

### Commercial opportunity

China has a high and rising prevalence of obesity and T2D, largely attributable to rapid urbanization, sedentary lifestyles, and dietary transitions. The growing burden of these metabolic disorders underscores a substantial commercial opportunity, with the combined obesity and type 2 diabetes market in China projected to exceed \$20 billion in 2034. Mazdutide, with its differentiated mechanism of action and favorable clinical and safety profile, is well positioned to capture a meaningful share of these markets.



### Path to market penetration

Mazdutide recently received regulatory approval in China, marking a milestone as a domestically developed, once-weekly dual GLP-1 and glucagon receptor agonist. As the third novel entrant after semaglutide and tirzepatide, it enters a competitive market. However, Innovent's strong biologics portfolio, commercial expertise, and local presence are expected to drive uptake. Mazdutide's robust clinical performance and novel MOA position it as a strong domestic alternative to semaglutide and tirzepatide.



### Market access and reimbursement

NRDL inclusion for Mazdutide 6 mg in T2D is expected by 2026, bringing it in line with other GLP-1 therapies currently reimbursed under the NRDL, such as semaglutide and dulaglutide. This inclusion will strengthen its market accessibility and competitiveness within the incretin segment.

# About the author



## Sahil Arora

### Healthcare Research and Data Analyst DRG Commercial Solutions

Mr. Arora is involved in primary and secondary market research to create syndicated landscape and forecast content and provide market insights into various therapy areas in China, such as NASH, prostate cancer, gastroesophageal cancer, obesity/overweight, crohn's disease, and ulcerative colitis. He has expertise in market forecasting, competitive intelligence, key opinion leader (KOL) identification, KOL profiling, and social media footprint analysis. He holds a master's degree in pharmaceutical management from NIPER Mohali in India.

### Clarivate coverage of the China market in 2025

- Type 2 Diabetes
- Obesity/Overweight
- Non-Small-Cell Lung Cancer
- Breast Cancer
- Ulcerative Colitis
- Gastroesophageal Cancer
- Non-Hodgkin's Lymphoma / Chronic Lymphocytic Leukemia
- Chronic Obstructive Pulmonary Disease
- Chronic Kidney Disease
- Heart Failure
- Crohn's Disease
- Multiple Myeloma
- Hepatocellular Carcinoma
- Psoriasis
- Biosimilars in Oncology and Immunology



# Think forward™

**Have a question?**

lsh.support@clarivate.com  
clarivate.com

+1 215 386 0100 (U.S.)

+44 (0) 20 7433 4000 (Europe)

## About Clarivate

Clarivate is the leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit [clarivate.com](https://www.clarivate.com)

© 2025 Clarivate. All rights reserved

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.